Ignite Creation Date:
2025-12-25 @ 1:34 AM
Ignite Modification Date:
2026-01-06 @ 7:59 AM
Study NCT ID:
NCT06750094
Status:
RECRUITING
Last Update Posted:
2025-12-19
First Post:
2024-12-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Sponsor:
Janssen Research & Development, LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-12-12
Start Date Type:
ACTUAL
Primary Completion Date:
2027-12-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-04-13
Completion Date Type:
ESTIMATED
First Submit Date:
2024-12-20
First Submit QC Date:
None
Study First Post Date:
2024-12-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-18
Last Update Post Date:
2025-12-19
Last Update Post Date Type:
ESTIMATED